Invention Grant
- Patent Title: T cells with increased immunosuppression resistance
-
Application No.: US15949018Application Date: 2018-04-09
-
Publication No.: US10689620B2Publication Date: 2020-06-23
- Inventor: Bruno Laugel , Kathrin Skibbe
- Applicant: Adaptimmune Limited
- Applicant Address: GB Abingdon, Oxfordshire
- Assignee: ADAPTIMMUNE LIMITED
- Current Assignee: ADAPTIMMUNE LIMITED
- Current Assignee Address: GB Abingdon, Oxfordshire
- Agency: Hamilton, Brook, Smith & Reynolds, P.C.
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@5dfe037e
- Main IPC: C12N5/0783
- IPC: C12N5/0783 ; C12N9/16 ; A61K39/00 ; A61K35/17 ; C07K14/725 ; C12N15/86
Abstract:
This invention relates to the treatment of cancer in an individual by administration of a population of modified T cells that express a recombinant cAMP phosphodiesterase (PDE) or a fragment thereof and an antigen receptor which binds specifically to cancer cells in the individual. Populations of modified T cells and methods of producing populations of modified T cells are provided, along with pharmaceutical compositions and methods of treatment.
Public/Granted literature
- US20180298338A1 T Cells With Increased Immunosuppression Resistance Public/Granted day:2018-10-18
Information query
